{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T20:48:17Z","timestamp":1761598097777},"reference-count":0,"publisher":"American Association for Cancer Research (AACR)","issue":"9","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In a phase I\/II study, chimeric antigen receptor T cells produced complete remissions in 88% of patients with refractory or relapsed follicular lymphoma, all of whom remained in remission after a median of 2 years of follow-up. The treatment induced cytokine release syndrome and neurotoxicity in 50% of patients, but none developed side effects more severe than grade 2.<\/jats:p>","DOI":"10.1158\/2159-8290.cd-nb2019-082","type":"journal-article","created":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T18:45:11Z","timestamp":1563821111000},"page":"OF4-OF4","update-policy":"http:\/\/dx.doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["CAR T-cell Therapy Yields Durable Remissions in FL"],"prefix":"10.1158","volume":"9","member":"1086","published-online":{"date-parts":[[2019,9,3]]},"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/9\/9\/OF4\/42276\/CAR-T-cell-Therapy-Yields-Durable-Remissions-in","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/9\/9\/OF4\/42276\/CAR-T-cell-Therapy-Yields-Durable-Remissions-in","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T02:06:41Z","timestamp":1654567601000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/9\/9\/OF4\/42276\/CAR-T-cell-Therapy-Yields-Durable-Remissions-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,1]]},"references-count":0,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,9,3]]},"published-print":{"date-parts":[[2019,9,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-nb2019-082","relation":{},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,1]]}}}